Pemvidutide Shows Promising Antifibrotic Effects in Phase IIb MASH Trial

Altimmune has reported positive topline results from its Phase IIb IMPACT trial evaluating pemvidutide, a dual glucagon/GLP-1 receptor agonist, in patients with metabolic dysfunction-associated steatohepatitis (MASH). The study met its primary objectives, demonstrating statistically significant improvements in key non-invasive markers of liver fibrosis compared with placebo at 48 weeks.

Pemvidutide produced meaningful reductions in Liver Stiffness Measurement (LSM) and Enhanced Liver Fibrosis (ELF) scores, with continued improvement observed from 24 weeks, suggesting sustained antifibrotic activity at both 1.2 mg and 1.8 mg doses. Additional significant benefits were seen across other liver health indicators, including corrected T1 (cT1), liver fat content, and alanine aminotransferase (ALT).

The therapy also delivered dose-dependent weight loss and was generally well tolerated, with low discontinuation rates and no serious treatment-related adverse events. Following an End-of-Phase II meeting, Altimmune confirmed alignment with the FDA on advancing pemvidutide into a registrational Phase III trial, planned for 2026.

22-12-2025